Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Exagen revenue
Exagen's revenue is $55.6 million.
What is Exagen's revenue?
- Exagen annual revenue for 2024 was 55.6M, 5.89% growth from 2023.
- Exagen's revenue growth from 2018 to 2024 is 71.52%.
- Exagen has 181 employees, and the revenue per employee ratio is $307,408.
- Exagen's peak quarterly revenue was $15.1M in 2024(q2).
- Exagen peak revenue was $55.6M in 2024.
- Exagen annual revenue for 2023 was 52.5M, 15.33% growth from 2022.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Exagen historical revenue
Exagen's peak revenue was $55.6M in 2024. The peak quarterly revenue was $15.1M in 2024(q2).
Exagen's revenue increased from $32.4m in 2018 to $55.6M currently. That's a 71.52% change in annual revenue.
Exagen annual revenue
Exagen annual revenue over time
| Fiscal year / year | Exagen revenue |
|---|---|
| 2018 | $32.4M |
| 2019 | $40.4M |
| 2020 | $42.0M |
| 2021 | $48.3M |
| 2022 | $45.6M |
| 2023 | $52.5M |
| 2024 | $55.6M |
Rate Exagen's financial transparency
Exagen annual growth
Exagen saw the greatest revenue growth in 2019, when revenue increased by 24.5%.
Exagen had the lowest revenue growth in 2022, when revenue changed by -5.66%.
Exagen annual growth rate over time
| Year | Exagen growth |
|---|---|
| 2019 | 24%↑ |
| 2020 | 4%↑ |
| 2021 | 15%↑ |
| 2022 | -6%↓ |
| 2023 | 15%↑ |
| 2024 | 6%↑ |
Exagen quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Exagen quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | - | - | $10.4M | $10.2M |
| 2020 | $9.6M | $8.9M | $10.8M | $12.7M |
| 2021 | $10.6M | $12.8M | $12.3M | $12.7M |
| 2022 | $10.4M | $7.6M | $14.7M | $12.8M |
| 2023 | $11.2M | $14.1M | $13.4M | $13.8M |
| 2024 | $14.4M | $15.1M | $12.5M | $13.7M |
Exagen jobs nearby
Do you work at Exagen?
Did Exagen meet its revenue projections?
Exagen financial information
| CEO | Fortunato Ron Rocca |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 181 |
| Date Founded | 2002 |
| Headquarters | Vista, California |
| Number of Locations | 1 |
| Revenue | $55.6M |
| Net Income | -$47,387,000 |
| Gross Proft | $33.1M (2024) |
| EBITDA | ($4.9M) (2018) |
| Tax Rate | -0.0% |
| Total Assets | $86,221,000 |
| Ticker | XGN |
Exagen jobs you might like
Exagen financing
Exagen received early financing of $5.4M on 2004-01-14.
| Series | Round size | Date |
|---|---|---|
| Series A | $5.4M | 01/2004 |
| Series B | $7M | 06/2005 |
| Series Unknown | $1M | 05/2009 |
| Series Unknown | $16.9M | 02/2011 |
| Series Unknown | $5.4M | 05/2011 |
| Series Unknown | $4.9M | 06/2011 |
| Debt Financing | $4.9M | 09/2011 |
| Debt Financing | $1M | 11/2011 |
| Series Unknown | $12.0M | 12/2011 |
| Series Unknown | $34.1M | 02/2012 |
| Series C | $5.3M | 09/2012 |
| Debt Financing | $124K | 11/2012 |
| Series D | $5M | 10/2013 |
| Debt Financing | $25M | 11/2013 |
| Debt Financing | $4.0M | 07/2014 |
| Debt Financing | $1.8M | 04/2015 |
| Debt Financing | $3M | 07/2015 |
| Series E | $16.8M | 01/2016 |
| Debt Financing | $2.1M | 06/2016 |
| Debt Financing | $25M | 10/2017 |
| Series F | $23M | 10/2017 |
| Series Unknown | $22.6M | 07/2019 |
| Post Ipo Equity | $69.1M | 03/2021 |
Exagen investors
| Investors | Security type |
|---|---|
| Tullis Health Investors | Series A |
| vSpring Capital | Series A |
| EPIC Ventures | Series A |
| Tullis Health Investors | Series B |
| vSpring Capital | Series B |
| EPIC Ventures | Series B |
| Tullis Health Investors | Series Unknown |
| Cottonwood Technology Fund | Series Unknown |
| Mesa Verde Venture Partners | Series Unknown |
| Sun Mountain Capital | Series Unknown |
| EPIC Ventures | Series Unknown |
| Tullis Health Investors | Series Unknown |
| Cottonwood Technology Fund | Series Unknown |
| Mesa Verde Venture Partners | Series Unknown |
| Sun Mountain Capital | Series Unknown |
| EPIC Ventures | Series Unknown |
| Tullis Health Investors | Series Unknown |
| Cottonwood Technology Fund | Series Unknown |
| Sun Mountain Capital | Series Unknown |
| Tullis Health Investors | Series Unknown |
| Cottonwood Technology Fund | Series Unknown |
| Sun Mountain Capital | Series Unknown |
| Tullis Health Investors | Series C |
| Cottonwood Technology Fund | Series C |
| Mesa Verde Venture Partners | Series C |
| Sun Mountain Capital | Series C |
| EPIC Ventures | Series C |
| CRG | Series D |
| Tullis Health Investors | Debt Financing |
| Cottonwood Technology Fund | Debt Financing |
| Mesa Verde Venture Partners | Debt Financing |
| Sun Mountain Capital | Debt Financing |
| EPIC Ventures | Debt Financing |
| CRG | Debt Financing |
| Tullis Health Investors | Debt Financing |
| Cottonwood Technology Fund | Debt Financing |
| Sun Mountain Capital | Debt Financing |
| CRG | Debt Financing |
| Innovatus Capital Partners | Debt Financing |
| H.I.G. BioHealth Partners | Series Unknown |
| Tullis Health Investors | Series Unknown |
| J. Hunt Holdings | Series Unknown |
| Sun Mountain Capital | Series Unknown |
Exagen competitors
Exagen's top competitor, Orthofix, earned an annual revenue of $799.5M.
Exagen's smallest competitor is SportsArt with revenue of $170.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Chronix Biomedical | $83,597 | $1.7M | 300 | - |
| Veravas | $44,868 | $1.3M | 12 | - |
| Paradise Genomics | $61,506 | $210,000 | 6 | - |
| SportsArt | $68,998 | $170,000 | 350 | - |
| Vasomedical | $73,544 | $1.6M | 317 | - |
| Medispec | $61,486 | $8.5M | 150 | - |
| Merz Inc | $62,199 | $50.0M | 764 | 33 |
| Conceptus | $67,982 | $140.7M | 125 | - |
| Cryo-Cell | $50,603 | $25.4M | 98 | - |
| GenScript | $72,821 | $390.8M | 3,000 | 50 |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Most in demand jobs
Zippia gives an in-depth look into the details of Exagen, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Exagen. The employee data is based on information from people who have self-reported their past or current employments at Exagen. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Exagen. The data presented on this page does not represent the view of Exagen and its employees or that of Zippia.
Exagen may also be known as or be related to EXAGEN INC., Exagen, Exagen Diagnostics, Inc. and Exagen Inc.